REFERENCES
2. Xiao Y, Wang Z, Zhao M, et al. Single-cell transcriptomics revealed subtype-specific tumor immune microenvironments in human glioblastomas. Front Immunol. 2022;13:914236.
3. Gautam A, Pandit B. IL32: The multifaceted and unconventional cytokine. Hum Immunol. 2021;82:659-67.
4. Hough JT, Zhao L, Lequio M, et al. IL-32 and its paradoxical role in neoplasia. Crit Rev Oncol Hematol. 2023;186:104011.
6. Shim S, Lee S, Hisham Y, et al. A Paradoxical effect of interleukin-32 isoforms on cancer. Front Immunol. 2022;13:837590.
7. Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28:1747-56.
8. Newman AM, Steen CB, Liu CL, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37:773-82.
9. Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24:1550-8.
10. Cloughesy TF, Mochizuki AY, Orpilla JR, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019;25:477-86.
11. Maeser D, Gruener RF, Huang RS. oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021:22.
12. Wang Q, Hu B, Hu X, et al. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell. 2018;33:152.
13. Yan H, He D, Qu J, et al. Interleukin-32γ promotes macrophage-mediated chemoresistance by inducing CSF1-dependent M2 macrophage polarization in multiple myeloma. Cancer Immunol Immunother. 2023;72:327-38.
14. Liu Y, Yan H, Gu H, et al. Myeloma-derived IL-32γ induced PD-L1 expression in macrophages facilitates immune escape via the PFKFB3-JAK1 axis. Oncoimmunology. 2022;11:2057837.
15. Meng D, Dong H, Wang C, Zang R, Wang J. Role of interleukin‑32 in cancer progression (Review). Oncol Lett. 2024;27:54.
16. Takagi K, Shimomura A, Imura J, et al. Interleukin-32 regulates downstream molecules and promotes the invasion of pancreatic cancer cells. Oncol Lett. 2022;23:14.
17. Takagi K, Imura J, Shimomura A, et al. Establishment of highly invasive pancreatic cancer cell lines and the expression of IL-32. Oncol Lett. 2020;20:2888-96.
18. Yan H, Dong M, Liu X, et al. Multiple myeloma cell-derived IL-32γ increases the immunosuppressive function of macrophages by promoting indoleamine 2,3-dioxygenase (IDO) expression. Cancer Lett. 2019;446:38-48.
19. Wen S, Hou Y, Fu L, et al. Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin β3-p38 MAPK signalling. Cancer Lett. 2019;442:320-32.
20. Wang G, Wang WY, Luo C, et al. IL-32-mediated caspase-43 induction: shaping macrophage differentiation & immunomodulation in glioblastoma multiforme. Indian J Med Res. 2025;161:702-9.
21. Sun Y, Qian Y, Chen C, et al. Extracellular vesicle IL-32 promotes the M2 macrophage polarization and metastasis of esophageal squamous cell carcinoma via FAK/STAT3 pathway. J Exp Clin Cancer Res. 2022;41:145.
22. Gu SM, Lee YS, Yoon DY, et al. Multifaceted role of interleukin-32 in inflammatory diseases and cancer. Biomed Pharmacother. 2026;194:118931.
23. Abdelfattah N, Kumar P, Wang C, et al. Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target. Nat Commun. 2022;13:767.
24. Sun S, Qian S, Wang R, et al. Targeting GOLPH3L improves glioblastoma radiotherapy by regulating STING-NLRP3-mediated tumor immune microenvironment reprogramming. Sci Transl Med. 2025;17:eado0020.
25. Alrosan AZ, Heilat GB, Al Subeh ZY, et al. The effects of statin therapy on brain tumors, particularly glioma: a review. Anticancer Drugs. 2023;34:985-94.
26. Tan SK, Jermakowicz A, Mookhtiar AK, Nemeroff CB, Schürer SC, Ayad NG. Drug repositioning in glioblastoma: a pathway perspective. Front Pharmacol. 2018;9:218.
27. Guillot F, Misslin P, Lemaire M. Comparison of fluvastatin and lovastatin blood-brain barrier transfer using in vitro and in vivo methods. J Cardiovasc Pharmacol. 1993;21:339-46.
28. Kiewe P, Neumann M, Wagner T, et al. Penetration of ifosfamide and its active metabolite 4-OH-ifosfamide into cerebrospinal fluid of patients with CNS malignancies. Cancer Chemother Pharmacol. 2011;67:27-33.
29. Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J Pharmacol Exp Ther. 2012;342:33-40.
30. Zhao HF, Wang J, Shao W, et al. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. Mol Cancer. 2017;16:100.
31. Mo F, Pellerino A, Soffietti R, Rudà R. Blood-brain barrier in brain tumors: biology and clinical relevance. Int J Mol Sci. 2021;22:12654.
